Literature DB >> 33593281

Serum miR-222 is independently associated with atrial fibrillation in patients with degenerative valvular heart disease.

Hualan Zhou1, Sen Lin2, Xia Li1, Dianxuan Guo1, Yun Wang1, Youdong Hu3.   

Abstract

BACKGROUND: Inflammation is involved in the progression of degenerative valvular heart disease (DVHD). microRNA-222 (miR-222) contributes to inflammation-mediated vascular remodeling, but its involvement in DVHD in relation to atrial fibrillation (AF) is unknown. This study aimed to investigate the changes in miR-222, interleukin (IL)-6, high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with DVHD complicated with AF.
METHODS: This was a case control study of patients with DVHD who were hospitalized at the Geriatrics Department of the Affiliated Huai'an Hospital of Xuzhou Medical University between 01/2017 and 08/2018. The participants were grouped according to the presence of AF, and serum miR-222, IL-6, hs-CRP, and NT-proBNP levels were compared.
RESULTS: There were fifty-two participants (28 males) in the DVHD with AF group, aged 60-80 years (73.0 ± 5.9 years). Sixty participants (31 males) were included in the DVHD without AF group, aged 60-80 years (71.9 ± 6.92 years). There were no significant differences in age, sex, body mass index, fasting blood glucose, triglycerides, cholesterol, and blood pressure between the two groups. The serum levels of miRNA-222, IL-6, hs-CRP, and NT-proBNP in DVHD patients were significantly higher in those with AF compared with the non-AF group (all P < 0.05). Correlation analyses revealed that IL-6, hs-CRP, and NT-proBNP levels were positively correlated with miR-222 levels in all patients (IL-6: r = 0.507, P < 0.01; hs-CRP: r = 0.390, P < 0.01; NT-proBNP: r = 0.509, P < 0.01).
CONCLUSIONS: Serum miR-222 was independently associated with AF in patients with DVHD.

Entities:  

Keywords:  Brain natriuretic peptide; Degenerative valvular heart disease; Interleukin-6; MicroRNA

Year:  2021        PMID: 33593281     DOI: 10.1186/s12872-021-01909-7

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  5 in total

Review 1.  Aortic Stenosis: Diagnosis and Treatment.

Authors:  Brian H Grimard; Robert E Safford; Elizabeth L Burns
Journal:  Am Fam Physician       Date:  2016-03-01       Impact factor: 3.292

2.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

4.  Differential Expression of MicroRNAs in Calcific Aortic Stenosis.

Authors:  Hai-Xia Xu; Yan Wang; Dong-Dong Zheng; Teng Wang; Min Pan; Jia-Hai Shi; Jian-Hua Zhu; Xiao-Fei Li
Journal:  Clin Lab       Date:  2017-07-01       Impact factor: 1.138

Review 5.  Circulating MicroRNAs as Potential Biomarkers of Atrial Fibrillation.

Authors:  Ananília Medeiros Gomes da Silva; Jéssica Nayara Góes de Araújo; Renata Caroline Costa de Freitas; Vivian Nogueira Silbiger
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.